# US 2021/0274726 A1 · THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0274726 A1
- Document ID: US20210274726A1
- Status: Published application
- Kind: A1
- Application number: 17/327,620
- Filed: 2021-05-21
- Published: 2021-09-09
- Earliest claimed: 2013-07-09
- Assignees: President and Fellows of Harvard College; Children's Medical Center Corporation
- Applicants: President and Fellows of Harvard College; The Children's Medical Center Corporation
- Inventors: Kiran Musunuru; Chad A. Cowan; Derrick J. Rossi
- Web page: https://patentgrep.com/patent/US20210274726A1

## CPC

- A01G 20/47: Vacuum or blower devices
- A47L 5/14: cleaning by blowing-off, also combined with suction cleaning
- A47L 11/24: Floor-sweeping machines, motor-driven
- A47L 11/4088: {Supply pumps; Spraying devices; Supply conduits}
- B05B 1/30: designed to control volume of flow, e.g. with adjustable passages {(B05B11/0094 takes precedence)}
- B05B 7/0075: {Nozzle arrangements in gas streams}
- B05B 15/60: Arrangements for mounting, supporting or holding spraying apparatus
- B08B 3/026: {Cleaning by making use of hand-held spray guns; Fluid preparations therefor}
- B08B 5/02: Cleaning by the force of jets, e.g. blowing-out cavities {(airguns or nozzles per se B05B1/005)}
- B08B 13/00: Accessories or details of general applicability for machines or apparatus for cleaning
- E01H 1/0809: {Loosening or dislodging by blowing (combined with suction E01H1/0863; with steam E01H1/10; removing snow by blowing E01H5/106; cleaning rails by blowing E01H8/105, E01H8/125; removing fog by blowing E01H13/00; cleaning joints in road construction by blowing E01C23/0906); Drying by means of gas streams (combined with snow or ice melting E01H5/10)}
- E01H 1/101: {Hydraulic loosening or dislodging, combined or not with mechanical loosening or dislodging, e.g. road washing machines with brushes or wipers (E01H1/005 takes precedence; cleaning rails E01H8/105, E01H8/125; applying liquids in general E01H3/00; scrubbing machines for floors or similar surfaces A47L11/26 - A47L11/30)}
- B05B 1/005: {Nozzles or other outlets specially adapted for discharging one or more gases}
- B05B 7/2475: {comprising a container carried on the back of the user}
- B05B 7/28: in which one liquid or other fluent material is fed or drawn through an orifice into a stream of a carrying fluid {(B05B7/262 takes precedence)}
- B05B 12/0022: {associated with means for restricting their movement}
- E01H 2001/0881: {Details for pneumatically dislodging or removing not related to the mouth-piece}
- A01G: HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING (picking of fruits, vegetables, hops or the like A01D46/00; propagating unicellular algae C12N1/12)
- A47L: DOMESTIC WASHING OR CLEANING (brushes A46B; cleaning quantities of bottles or of other hollow articles of one kind B08B9/00; laundry D06F); SUCTION CLEANERS IN GENERAL (cleaning in general B08)
- B05B: SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES (spray-mixers with nozzles B01F25/72; processes for applying liquids or other fluent materials to surfaces by spraying B05D)
- B08B: CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
- E01H: STREET CLEANING; CLEANING OF PERMANENT WAYS; CLEANING BEACHES; DISPERSING {OR PREVENTING} FOG IN GENERAL {CLEANING STREET OR RAILWAY FURNITURE OR TUNNEL WALLS}(cleaning in general B08B)

## Abstract

Disclosed herein are methods, compositions, and kits for high efficiency, site-specific genomic editing of cells for treating or preventing genetic blood disorders.

## Claims

### Claim 1

A method for treating or preventing a disorder associated with expression of a SCD-associated polynucleotide sequence in a subject, the method comprising (a) altering a target SCD-associated polynucleotide sequence in a cell ex vivo by contacting the SCD-associated polynucleotide sequence with a clustered regularly interspaced short palindromic repeats-associated (Cas) protein and from one to two ribonucleic acids, wherein the ribonucleic acids direct Cas protein to and hybridize to a target motif of the target SCD-associated polynucleotide sequence, wherein the target SCD-associated polynucleotide sequence is cleaved, and (b) introducing the cell into the subject, thereby treating or preventing a disorder associated with expression of the SCD-associated polynucleotide sequence.

### Claim 2

A method for treating or preventing a disorder associated with expression of a SCD-associated polynucleotide sequence in a subject, the method comprising (a) altering a target SCD-associated polynucleotide sequence in a cell ex vivo by contacting the SCD-associated polynucleotide sequence with a clustered regularly interspaced short palindromic repeats-associated (Cas) protein and from one to two ribonucleic acids, wherein the ribonucleic acids direct Cas protein to and hybridize to a target motif of the target SCD-associated polynucleotide sequence, wherein the target SCD-associated polynucleotide sequence is cleaved; (b) contacting the cleaved target SCD-associated polynucleotide sequences with an exogenously introduced DNA repair template to initiate homology-directed repair of the target SCD-associated polynucleotide; and (c) introducing the cell into the subject, thereby treating or preventing a disorder associated with expression of the SCD-associated polynucleotide sequence.

### Claim 3

A method for treating or preventing a disorder associated with expression of an HBB gene sequence in a subject, the method comprising (a) altering a target HBB gene sequence in a cell ex vivo by contacting the HBB gene sequence with a clustered regularly interspaced short palindromic repeats-associated (Cas) protein and from one to two ribonucleic acids, wherein the ribonucleic acids direct Cas protein to and hybridize to a target motif of the target HBB gene sequence, wherein the target HBB gene sequence is cleaved, and (b) introducing the cell into the subject, thereby treating or preventing a disorder associated with expression of the HBB gene sequence.

### Claim 4 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the disease is sickle cell disease.

### Claim 5 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the Cas protein is Streptococcus pyogenes Cas9 protein or a functional portion thereof selected from the group consisting of a DNA binding domain, at least one RNA binding domain, a helicase domain, and an endonuclease domain.

### Claim 6 (depends on 4)

A method according to claim 4, wherein the Cas protein is Streptococcus pyogenes Cas9 protein.

### Claim 7 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the Cas protein is complexed with the one to two ribonucleic acids.

### Claim 8 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the target motif is G(N)19NGG or (N)20NGG.

### Claim 9 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the cell is selected from the group consisting of a peripheral blood cell, a stem cell, a pluripotent cell, a hematopoietic stem cell, a CD34+ cell, a CD34+ mobilized peripheral blood cell, a CD34+ cord blood cell, a CD34+ bone marrow cell, a CD34+CD38-Lineage-CD90+CD45RA− cell, a primary human cell, a non-transformed human cell, and combinations thereof.

### Claim 10 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the Cas protein is encoded by a nucleic acid sequence comprising a modified nucleic acid selected from the group consisting of pseudouridine, 5-methylcytodine, 2-thio-uridine, 5-methyluridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5,6-dihydrouridine-5′-triphosphate, and 5-azauridine-5′-triphosphate.

### Claim 11 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein at least one of the ribonucleic acids is a modified ribonucleic acid comprising one to two modified nucleotides selected from the group consisting of pseudouridine, 5-methylcytodine, 2-thio-uridine, 5-methyluridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5,6-dihydrouridine-5′-triphosphate, and 5-azauridine-5′-triphosphate.

### Claim 12 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the target motif is located between position 5246806 and position 5248263 of human chromosome 11.
